Faculty of Health, Medicine and Behavioural Sciences
Availability:
Available for supervision
Dr Lauren Aoude is a research leader at the University of Queensland (UQ) Frazer Institute. Her research program explores barriers to precision oncology, and establishes more accurate prognostics to enhance therapeutic options for oesophageal adenocarcinoma (OAC) and melanoma patients. Her research integrates genomic sequencing data with clinical, pathological and imaging information. Recent work includes the establishment of patient-derived organoid models to enable a personalised medicine approach.
During her PhD (completed Nov 2014, QIMR Berghofer) she was a key member of international collaborations that significantly enhanced the understanding of melanoma susceptibility in at-risk families. Dr Aoude joined UQ as an NHMRC Early Career Fellow (2016-2021), where she led projects exploring precision medicine for metastatic melanoma and oesophageal cancer. In 2021, she was awarded a UQ Amplify fellowship to pursue research while expanding teaching and mentoring opportunities, including an on-going course co-ordinator role in the Master of Medicine Skin Cancer Program.
In 2025, she was awarded an NHMRC (EL2) Emerging Leader Fellowship. Her program vision is to better inform treatment decisions and improve health outcomes for patients through the integration of genomics into the clinic.
Faculty of Health, Medicine and Behavioural Sciences
Availability:
Not available for supervision
Dr Sandra Brosda is a Research Fellow within the Surgical Oncology group led by Professor Andrew Barbour.
Dr Brosda was awarded a PhD in bioinformatics and cancer genetics from the University of Queensland in November 2020. Her research focused on biomarker discovery and intra-tumour heterogeneity and tumour evolution in oesophageal adenocarcinoma (OAC). In 2021, Dr Brosda was awarded a Cure Cancer Australia PdCCRS grant and an MSH project grant to further investigate tumour evolution to improve precision medicine in OAC.
She has been involved in research projects covering genetics, epigenetics, spatial transcriptomics, radiomics, ctDNA and quality of life assessments in the context of cancer. Overall, her research applies bioinformatics tools and approaches to cancer genomics to improve precision medicine and health outcomes for patients with melanoma, oesophago-gastric cancer and pancreatic cancer.
Faculty of Health, Medicine and Behavioural Sciences
Availability:
Available for supervision
Media expert
After completing his BSc and MSc (Hons) at the University of Canterbury (NZ), Dylan worked for five years as a Research Scientist at Antisoma Research Limited (London, UK), developing antibody-enzyme fusion proteins for cancer therapy. He returned to New Zealand to carry out his PhD research into antidepressant pharmacogenomics at the University of Otago. Afterwards, he continued working at the University of Otago as a Research Fellow, studying the biological function of genes involved with inflammatory bowel disease. Dylan moved to the United States in 2009 to perform postdoctoral training, researching the functional genetics of the VEGF-pathway and its relationship with cancer at the University of Chicago and, subsequently, the University of North Carolina, Chapel Hill.
In 2013, Dylan began working at QIMR Berghofer and has undertaken the functional follow-up of large-scale genetic studies of breast, endometrial and ovarian cancer to identify the likely causal variants and genes that mediate associations with cancer risk and survival. He has been awarded both internal and NHMRC grant funding to support these studies. Since 2019, Dylan has held an Honorary Associate Professorship at UQ
As of early 2021, Dylan has authored one conference report, two editorials, two book chapters, six reviews and 31 original research articles. He is first or last author on 20 of these publications and 27 of his publications have been cited at least 10 times. According to CiteScore, since 2010, 53% of his articles have been published in journals ranked in the top 10% and 19% of hispublications are in the 10% most cited publications worldwide.
Clara Jiang is a postdoctoral research fellow at the Institute for Molecular Bioscience, the University of Queensland. Clara’s research focuses on using genomic and transcriptomic analysis to investigate the genetic basis of cardiovascular and psychiatric disorders, with a particular focus on female health, as well as using statistical genomic approaches to explore possible opportunities for drug repurposing. Clara graduated from the University of Queensland with Bachelor of Advanced Science (First Class Honours) in 2017, and was awarded the University Medal. Clara was awarded her PhD at the University of Queensland in 2021, where she utilised bioinformatic approaches and molecular experiments to decipher the genetic aetiology of breast cancer, specifically the regulatory role of transposons or ‘jumping genes’ in modulating the transcriptional landscape in the cancer state. Clara is also a UQ Wellness ambassador and an advocate for promoting equity, diversity and inclusion in academia.
Faculty of Health, Medicine and Behavioural Sciences
Affiliate of Dermatology Research Centre
Dermatology Research Centre
Faculty of Health, Medicine and Behavioural Sciences
Availability:
Available for supervision
Media expert
Professor Khosrotehrani is a clinical scientist, dircetor of the Frazer institute, the university of Queensalnd, sharing his passion for academic medicine and translation of science discorveries into real world solutions for patients. Prof Khosrotehrani is a dermatologist, interested in skin biology, regenerative medicine and skin cancer. He leads the Experimental Dermatology Group at the University of Queensland Frazer Institute within the Translational Research Institute in Brisbane, Australia. Dr Khosrotehrani obtained his MD from the Cochin-Port Royal School of Medicine at René Descartes University, Paris, France, where he specialized in Dermatology. He is a former graduate of the Ecole Normale Supérieure and the Institut Pasteur of Paris (Université Paris VI, Pierre et Marie Curie) where he obtained a PhD in Physiology and Physiopathology. He is a fellow of the Australian College of Dermatologists and a practising dermatologist at the Princess Alexandra Hospital, Prince Charles Hospital and the Skin and Cancer Foundation’s Queensland Institute of Dermatology.
As the inaugural St Baker-Soyer chair of Dermatology at the University of Queensland, Professor Khosrotehrani is a national leader in the discipline of Dermatology. He is a board director at the Australasian College of Dermatologists and the Queensland Skin and Cancer Foundation and the director of the Dermatology Department at the Princess Alexandra Hospital. He has held multiple leadership roles as past-President of the Australasian Society for Dermatology Research, Editor in chief of the Australasian Journal of Dermatology and board member of the International Society of investigative Dermatology.
During his post-doctoral training at Tufts-New England Medical Center, Boston, USA, Dr. Khosrotehrani helped establish the contribution of fetal stem cells to tissue repair by demonstrating their multipotent capacity with a specific potency towards the endothelial lineage. The originality of this work was acknowledged by the NHMRC through an achievement award (2011) and an NHMRC excellence award (2016). The main focus of his laboratory is on regenerative medicine and stem cell biology in particular in injury response in skin wounds and skin cancer and how these responses contribute to cancer initiation and progression. Translating his laboratory findings, Dr Khosrotehrani is leading innovative clinical trials in wound healing, keratinocyte cancers and melanoma.
Faculty of Health, Medicine and Behavioural Sciences
Availability:
Available for supervision
I am a Principal Investigator (PI) and a senior research officer (SRO) at Mater research – UQ with excellent clinical and research laboratory skills and expertise in conducting and analyzing laboratory assays and resolving complex research and clinical laboratory problems. I can describe myself as determined, reliable, studious, conscientious, attentive, industrious, diligent, and focused on the timely, quality completion of all lab procedures. I am able to work well under pressure and time constraints within high-volume environments both independently and in collaboration within a team. I am also a highly self-motivated and career-oriented individual with a genuine interest in addressing cancer molecular mechanisms with the goal of developing novel cancer therapeutics and immunotherapy focusing on tumor microenvironment, immunoregulation and signaling pathways in cancer and metastasis.